Somatostatin Analogs Market To Reach $11.1 Billion By 2030

Somatostatin Analogs Market Growth & Trends

The global somatostatin analogs market size is anticipated to reach USD 11.1 billion by 2030 and expand at a CAGR of 13.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing awareness of diseases such as acromegaly and neuroendocrine tumors is expected to be the vital impact rendering driver.

Acromegaly is a chronic endocrine condition caused by excessive growth hormone production, often due to a pituitary adenoma. In 2023, approximately 4,600 people per million globally were affected by acromegaly, with an estimated 116.9 new cases diagnosed annually per million, a number that continues to rise. The disorder is usually diagnosed around age 40 in men and 45 in women, though it often begins in the third decade of life. Hence, the increasing prevalence of acromegaly drives the somatostatin analogs market.

The growing rate of NET diagnoses in countries such as South Korea, Japan, and India and increasing per capita income are significant market drivers. In addition, rising investments from pharmaceutical companies are expected to create lucrative growth opportunities. Existence of different online portals providing related information on various diseases is anticipated to create awareness among the population. For instance, Neuroendocrine Cancer Awareness Network provides all the information related to their symptoms, available treatment options and disease management.

 Request a free sample copy or view report summary: Somatostatin Analogs Market Report

Somatostatin Analogs Market Highlights

• By type, octreotide dominated the somatostatin analogs market, with a revenue share of 36.3% in 2024.

• The pasireotide segment is expected to grow at the fastest CAGR over the forecast period.

• By application, the NET segment dominated the somatostatin analogs market with the largest revenue share in 2024 and is expected to grow at the fastest CAGR over the forecast period.

• Hospitals led the somatostatin analogs market, accounting for the largest revenue share in 2024.

• Hospitals dominated the market in 2024, and the clinics segment is expected to grow at the fastest CAGR of 14.4% over the forecast period.

• North America dominated the global market owing to the presence of key players in the region.

Somatostatin Analogs Market Segmentation

Grand View Research has segmented the global somatostatin analogs market based on type, application, end-use, and region:

Somatostatin Analogs Type Outlook (Revenue, USD Million; 2018 - 2030)

• Octreotide

• Lanreotide

• Pasireotide

• Others

Somatostatin Analogs Application Outlook (Revenue, USD Million; 2018 - 2030)

• Acromegaly

• NET

• Others

Somatostatin Analogs End-use Outlook (Revenue, USD Million; 2018 - 2030)

• Hospitals

• Clinics

• Others

Somatostatin Analogs Regional Outlook (Revenue, USD Million; 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

  • Russia

• Asia Pacific

  • India

  • China

  • South Korea

  • Hong Kong

  • Australia

  • Singapore

  • Japan

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • Kuwait

  • Saudi Arabia

  • South Africa

  • UAE

List of Key Players in the Somatostatin Analogs Market

• Novo Nordisk A/S

• Pfizer Inc. 

• Eli Lilly and Company

• Medical Device Business Services, Inc.

• Johnson & Johnson Services, Inc.

• Stryker

• Ultragenyx Pharmaceutical Inc. 

• Alexion Pharmaceuticals, Inc.